The recent end of a 340B program waiver for hospitals is wrong, hurts hospitals and their patients, and is bound [...] …
Category: Providers
The community benefits provided by 340B hospitals surged by $16.5 billion, or 24%, in the latest year analyzed by a [...] …
The Health Resources and Services Administration (HRSA) confirmed today it is ending a 340B program waiver issued early in the [...] …
Genentech, Sanford Health, and Carolina Health Centers’ 340B reform group, 340B Working Table, spent $110,000 on lobbying and gained eight [...] …
GlaxoSmithKline (GSK) recently restricted 340B pricing on Jesduvroq, an anemia treatment, when providers dispense it through contract pharmacies. GSK contractor [...] …
Drug manufacturer Genentech has asked health systems and hospitals about possible 340B program compliance violations involving split-billing software settings. Staff [...] …
Drug manufacturer Teva this week added a drug to the hospital contract pharmacy restrictions it first implemented in June. The [...] …
A final rule to implement the 340B administrative dispute resolution (ADR) process arrived this week at the last stage of [...] …
More than 400 hospitals risk losing 340B eligibility if Congress does not extend exemptions authorized during the public health emergency [...] …
The majority of 340B disproportionate share hospitals (DSH) provide charity care at lower rates than the national hospital average, found [...] …